Source-grounded facts extracted from Corvus Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Corvus Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-11 meeting.
“Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers. Votes For Votes Against Abstain Broker Non-Votes 58,936,532 1,971,370 64,329 12,049,623”
Shareholder Votes
Corvus Pharmaceuticals, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2026-06-11 meeting.
“Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. Votes For Votes Against Abstain 72,864,335 105,674 51,845”
Shareholder Votes
Corvus Pharmaceuticals, Inc. shareholders approved Election of Class I Directors at the 2026-06-11 meeting.
“Proposal No. 1 — Election of Directors The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until his or her respective successor is elected and qualified or appointed, or the earlier of his or her death, resignation or removal. Class III Director Nominees Votes For Votes Withheld Broker Non - Votes Richard A. Miller, M.D. 58,275,179 2,697,052 12,049,623 Linda S. Grais, M.D., J.D. 53,185,380 7,786,851 12,049,623”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $13.7 million.
“Net loss for the three months ended March 31, 2026 was $13.7 million”
Material Agreements
Corvus Pharmaceuticals, Inc. entered into Amended and Restated Open Market Sale Agreement with Jefferies LLC valued at maximum aggregate offering price of up to $200,000,000 (effective 2026-03-13).
“On March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement SM (the “Amended Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having a maximum aggregate offering price of up to $200,000,000.”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 12, 2026, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2025 and its financial position as of December 31, 2025, and provided a business update.”
Richard van den Broek was appointed as Director at Corvus Pharmaceuticals, Inc..
“appointed Richard van den Broek to the Board.”
Material Agreements
Corvus Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors ) valued at combined offering price of $1.7312 (effective 2024-05-01).
“On May 1, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein, including the Company’s chief executive officer and certain of the Company’s existing institutional investors, including investors affiliated with certain of the Company’s directors (collectively, the “Investors”).”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.
“Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2023 and its financial position as of December 31, 2023, and provided a business update.”
Edith P. Mitchell departed as Director at Corvus Pharmaceuticals, Inc..
“Edith P. Mitchell, M.D., a director of Corvus Pharmaceuticals, Inc. has passed away.”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: net income The net loss for the three months ended September 30, 2023 was $6.0 million.
“Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.
“Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.”
Shareholder Votes
Corvus Pharmaceuticals, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-15 meeting.
“Votes For Votes Against Abstain Broker Non-Votes 25,550,695 348,929 177,941 10,073,471”
Shareholder Votes
Corvus Pharmaceuticals, Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLC as independent registered accounting firm at the 2023-06-15 meeting.
“Votes For Votes Against Abstain 35,873,795 104,973 172,268”
Shareholder Votes
Corvus Pharmaceuticals, Inc. shareholders approved Election of Class I directors at the 2023-06-15 meeting.
“Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Richard A. Miller, M.D. 26,009,538 68,027 10,073,471 Linda S. Grais, M.D. J.D. 25,210,111 867,454 10,073,471”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $7.9 million.
“The net loss for the three months ended March 31, 2023 was $7.9 million compared to a net loss of $8.3 million for the same period in 2022.”
Material Agreements
Corvus Pharmaceuticals, Inc. terminated Sales Agreements with Jefferies LLC valued at At-the-Market Offering Program with aggregate offering price up to $50.0 million (2020) and up to $4 (effective 2023-03-28).
“On March 28, 2023, the Company terminated the Sales Agreements effective immediately. As a result, the At-the-Market Offering Programs under each of the 2020 Sales Agreement and 2021 Sales Agreement are no longer available for use.”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“On March 28, 2023, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2022 and its financial position as of December 31, 2022, and provided a business update.”
Earnings Releases
Corvus Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.
“Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results”
Listing & Compliance Notices
Corvus Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“ule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.